Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
about
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study GroupOutcome of 67 patients with solid tumors relapsed after high-dose chemotherapy and peripheral blood stem cell transplantation.A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Current status and future perspectives in the treatment of advanced testicular cancer.Recent advances in management of patients with platinum-refractory testicular germ cell tumors.A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial.Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours.The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update.Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).Current Management of Refractory Germ Cell Tumors and Future Directions.Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1.High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer.Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer.Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors.Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
P2860
Q33344289-A6DEB6E6-2890-4F4D-A3AF-507F61A19F97Q33348201-02056539-08CB-445F-BDF9-13F544EB9DDFQ33402598-34B85862-4AEF-4A75-A6E0-8E2E1BB32B6EQ34612225-C394CBEB-B352-4769-A332-588B34DE177EQ36389456-5FDDB9D1-3A08-44C0-8FE8-1D9178C8F1EDQ36615043-AEC83702-48E5-4586-BDCC-BC675245EB65Q36694538-3F747158-EF32-41BF-A721-D6D19DDA0D38Q37182159-136E0349-0C2B-4CBC-A7AB-1E564A0061FFQ37905875-F8F46FC2-778D-469D-872B-4ABA79CE6D47Q38275537-51ED4387-8815-4565-86B1-C2A753EC4FFAQ38755132-833D8D18-F2BF-481B-B084-0D14E89C92A1Q41560943-EA9B1289-01AF-4066-9661-54EAD21F8C41Q43993231-6074A6AA-00D7-4FF9-84EA-71EF6D500F25Q44068928-FCD18441-664C-43D4-B6FD-72464A29F590Q44197097-B1A1D195-63F2-4AA4-A3E8-A8A8EFDAD2B9Q55433478-43E87EA8-E36F-479F-BBD7-BA3532A60573
P2860
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@ast
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@en
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@nl
type
label
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@ast
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@en
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@nl
prefLabel
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@ast
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@en
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@nl
P2093
P1476
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
@en
P2093
A Harstrick
C Bokemeyer
H J Schmoll
N Niederle
P Schöffski
P304
P356
10.1200/JCO.1999.17.2.512
P407
P577
1999-02-01T00:00:00Z